Improving Prognosis in Liver Cancer Patients
Author Information
Author(s): Vitale Alessandro, Navaglia Filippo, RamÃrez Morales Rafael, Frigo Anna Chiara, Basso Daniela, D'Amico Francesco, Zanus Giacomo, Bonsignore Pasquale, Farinati Fabio, Burra Patrizia, Senzolo Marco, Grigoletto Francesco, Plebani Mario, Cillo Umberto
Primary Institution: Università di Padova, Padova, Italy
Hypothesis
The combination of AFP mRNA and VEGF levels can improve prognostic predictions for HCC patients evaluated for curative therapies.
Conclusion
Preoperative determination of AFP mRNA status and VEGF may refine the prognostic evaluation of HCC patients and improve the selection process for potentially curative therapies.
Supporting Evidence
- 40% of patients had AFP mRNA in the blood.
- 35% had VEGF levels above 23 pg/ml.
- Surgery was performed in 47% of patients.
- Median follow-up was 19 months.
Takeaway
Doctors can check certain markers in the blood to better understand how serious liver cancer is and decide on the best treatment.
Methodology
A prospective observational study was conducted with 124 HCC patients, assessing AFP mRNA and VEGF levels before therapy.
Limitations
The small sample size limits the ability to draw definitive conclusions.
Participant Demographics
Median age was 62 years, with a male/female ratio of 98/26; all patients had cirrhotic livers.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website